摘要
目的:探究冠状动脉慢血流(CSF)患者采用曲美他嗪、瑞舒伐他汀联合治疗对血管内皮功能的影响。方法:选取100例CSF患者,随机将其分为对照组和研究组各50例。对照组给予瑞舒伐他汀治疗,研究组给予曲美他嗪、瑞舒伐他汀联合治疗,治疗3个月,比较两组的疗效。结果:研究组总有效率和肱动脉血管内皮依赖性舒张功能(FMD)明显优于对照组;患者的血管内皮素-1(ET-1)、超敏C反应蛋白(hs-CRP)水平均低于对照组,且一氧化氮(NO)水平明显更高(P <0.05)。两组不良反应发生率比较差异无统计学意义。结论:对CSF患者采用曲美他嗪、瑞舒伐他汀联合治疗能有效改善其血管内皮功能,安全可靠。
Objective: To investigate the effects of trimetazidine combined with rosuvastatin on vascular endothelial function in coronary slow flow (CSF) patients. Methods: One hundred cases of CSF patients were selected and randomly divided into a control group and a study group with 50 cases each. The control group was treated with rosuvastatin while the study group was treated with trimetazidine and rosuvastatin, and the treatment was lasted for 3 months. Therapeutic effects were compared between the two groups. Results: The total effective rate and endothelium-dependent diastolic function (FMD) of brachial artery were significantly better, the levels of endothelin-1 (ET-1) and hypersensitive C-reactive protein (hs-CRP) were lower and nitric oxide (NO) level was significantly higher in the study group than the control group (P<0.05). There were no significant differences in adverse reactions between the two groups (P>0.05). Conclusion: Rimetazidine combined with rosuvastatin in the treatment of CSF patients can effectively improve vascular endothelial function with better safety and reliability.
作者
吴彩云
王高明
孙志刚
WU Caiyun;WANG Gaoming;SUN Zhigang(Department of Cardiology, the First People’s Hospital of Fuzhou,Jiangxi Fuzhou 344000,China)
出处
《上海医药》
CAS
2019年第17期25-27,共3页
Shanghai Medical & Pharmaceutical Journal
